![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterized by cyclin D1 overexpression as a result of the t(11;14) chromosomal translocation, and by biological and clinical heterogeneity with frequent extranodal dissemination. There is no consensus or standard for initial therapy or for treatment of relapsed disease, and no proven curative therapy exists. Nonetheless, considerable progress in treatment response and survival has been realized over the past several years, and the disease remains an important focus of preclinical and clinical research. Advances in the biologic understanding of MCL, new molecular targets and therapeutic strategies, and the applications of biomarkers for risk stratification and molecular targeting were reviewed at a recent MCL Workshop. These are summarized herein, and are intended as both a status report on areas of active investigation and to serve as a template for future research.
Acknowledgments
The authors thank LRF staff members Kathleen Brown, James Testaverde, and Melinda B. Tanzola, PhD for assistance in drafting the proceedings of this meeting.
Declaration of interest: The work presented at this meeting was supported by grants from the Lymphoma Research Foundation Mantle Cell Lymphoma Initiative and the MCL Consortium. Each presenter whose work is included herein reviewed and approved the summary of that work. Meeting support was provided by the LRF and by Millennium: The Takeda Oncology Company. All coauthors are members of the LRF Scientific Advisory Board. The work summarized in this report has been supported in part by LRF Mantle Cell Lymphoma Initiative and Correlative grants.